New iQROS’s Updates Ensure Clinical Study Risk-Planning Consistency, Efficency, Safety

Comments Off on New iQROS’s Updates Ensure Clinical Study Risk-Planning Consistency, Efficency, Safety

Customer input and feedback drives greater functionality

Nov. 20  2015, Irvine, Calif. — Efficiently, effectively and affordably executing a clinical trial is an arduous task. Just ask front-line staff implementing risk-based monitoring for promising pharmaceuticals undergoing clinical study. That’s why when users of iQROS™ asked for even greater flexibility and functionality for managing risk-based monitoring, Kestrel Biologic listened and updated iQROS with new, enhanced functionality for identifying and tracking protocol deviations.

iQROS is an interactive, quality and risk-based oversight software system offering secure web-based visibility and access into study oversight status. Developed for small- and medium-sized pharmaceutical companies and clinical research organizations, iQROS effectively captures risk planning and monitoring activities in a dynamic, living database across clinical studies. The easy-to-use software provides password-protected transparency into the complete oversight process, but more importantly, the software streamlines the reporting process for all monitoring activities.

“The new tools within iQROS are the result of customer input and feedback,” said Lorne Cheeseman, CEO, Kestrel Biologic. “Protocol deviations are now structured to ensure that deviations are captured consistently and updated simultaneously making the overall reporting process quicker and easier for identifying, tracking and managing risks.”  

The updated version effectively captures all the data related to the risk plan and the monitoring activities driven out of that plan.

“Tracking protocol deviations using iQROS will save the study manager’s time and resources,” Cheeseman concluded. “The updates will ensure that deviations are documented efficiently and consistently and making it easier to generate a detailed and accurate report at the end of the study.”

About Kestrel Biologic

Based in Southern California, Kestrel Biologic is committed to improving clinical operations with its iQROS interactive, quality and risk oversight system. For more information about iQROS or Kestrel Biologic, go to www.kestrelbiologic.com or contact a company representative at O: +1 (949) 200-8885 or info@Kestrelbiologic.com.